We extend our sincere appreciation to the families clinicians FDA presenters and committee members who participated in todays panel and to all those who provided input and comments both in the written record and in the open public hearing SRP9001 is intended to treat the underlying cause of Duchenne which is characterized by mutations in the dystrophin gene that results in the lack of dystrophin protein